Evidence map›Paper›PMID 31742250›Full record

Observational studyOphthalmology. Glaucoma

Comparing 10-2 and 24-2 Visual Fields for Detecting Progressive Central Visual Loss in Glaucoma Eyes with Early Central Abnormalities.

Zhichao Wu, Felipe A Medeiros, Robert N Weinreb, Christopher A Girkin, Linda M Zangwill

Abstract readComparative StudyMulticenter StudyObservational Study
In one paragraph

Observational study in Ophthalmology. Glaucoma. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Predicting 60-4 visual field tests using 3D facial reconstruction.The British journal of ophthalmology · 2023
    Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Observational
  18. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhichao WuHamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California.
Felipe A MedeirosDuke Eye Center and Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina.
Robert N WeinrebHamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California.
Christopher A GirkinDepartment of Ophthalmology, University of Alabama at Birmingham, Birmingham, Alabama.
Linda M ZangwillHamilton Glaucoma Center, Department of Ophthalmology, University of California, San Diego, La Jolla, California.

Funding

African Descent And Glaucoma Evaluation Study (ADAGES)U10EY014267 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2002 to 2010
$13.2M
Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Derek Stuart Welsbie · 2012 to 2026
$10.3M
Diagnostic Innovations in Glaucoma:Structural AssessmentR01EY011008 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 1995 to 2015
$8.7M
Diagnostic Innovations in Glaucoma Study (DIGS): High Myopia and Advanced DiseaseR01EY027510 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2017 to 2026
$5.3M
Diagnostic Innovations in Glaucoma Study (DIGS): Functional ImpairmentR01EY021818 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MEDEIROS, FELIPE · 2011 to 2015
$3.4M
African Descent and Glaucoma Evaluation (ADAGES) II: Glaucoma ProgressionR01EY019869 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2010 to 2014
$2.8M
African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the lamina cribrosa in progressionR01EY026574 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FAZIO, MASSIMO ANTONIO, GIRKIN, CHRISTOPHER ANTHONY · 2017 to 2020
$2.6M
NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY011008NEI NIH HHS R01 EY019869NEI NIH HHS R01 EY021818NEI NIH HHS R01 EY026574NEI NIH HHS R01 EY027510NEI NIH HHS U10 EY014267
6 · The paper itself

Abstract

Purpose: To compare the ability of 10-2 visual field tests and central 12 locations of the 24-2 tests (C24-2) to detect central visual field progression in glaucoma eyes with early central visual field abnormalities. Design: Observational cohort study. Participants: Three-hundred eyes of 180 participants with glaucoma or ocular hypertension. Methods: Participants with both 10-2 and 24-2 tests performed on ≥3 visits over ≥1-year period were included to estimate the longitudinal variability of 10-2 and C24-2 visual field mean deviation (MD). The variability estimates were then used to reconstruct real-world visual field results by computer simulations, in a scenario where eyes had a baseline 10-2 and C24-2 MD was -2 dB and exhibited various rates of change (-0.25, -0.50, -0.75 and -1.00 dB/year), and the time to detect these changes were evaluated using trend-based analyses. Main Outcome Measures: Time required to detect progression. Results: Overall, the time to detect central visual field progression was reduced by 7-9% using the 10-2 compared to C24-2 MD values, equivalent to a total reduction of 0.1-0.3 dB lost. For example, 90% of eyes with a central 10-2 or C24-2 MD loss of -0.50 dB/year would be detected after 5.0 and 5.5 years of semi-annual testing respectively, or after 3.4 and 3.7 years respectively for eyes with a -1.00 dB/year loss. Conclusions: Trend-based analyses using 10-2 MD resulted in a mild reduction (7-9%) in the time to detect central visual field progression compared to C24-2 MD in glaucoma eyes with early central visual field abnormalities. Further studies are needed to determine whether other progression analyses can better exploit the increased sampling of 10-2 tests. These findings provide evidence-based guidance on the potential value-add of 10-2 testing in the clinical management of glaucoma patients.

Indexed as

AdultAgedAged, 80 and overDisease ProgressionFemaleFollow-Up StudiesGlaucomaHumansIntraocular PressureMaleMiddle AgedOptic DiskProspective StudiesScotomaTime FactorsVisual Fields10-2GlaucomaProgressionVisual Field

Identifiers

PMID31742250
PMCPMC6860370

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.